Evidence map›Paper›PMID 40253526›Full record

ReviewCancer gene therapy2025

ARL6IP5 in cancers: bidirectional function and therapeutic value.

Zenan Hu, Hanxun Yue, Liang Qiao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zenan Hu *The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Hanxun Yue *The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.ORCID http://orcid.org/0009-0003-4310-7000
Liang QiaoStorr Liver Centre, Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Westmead, NSW, Australia. liang.qiao@sydney.edu.au.ORCID http://orcid.org/0000-0002-4723-8935

Funding

Natural Science Foundation of Gansu Province 22JR5RA902
6 · The paper itself

Abstract

ARL6IP5 (ADP-ribosylation-like factor 6 interacting protein 5) plays an important role in a variety of physiological or pathological processes, including in cancers. However, the biological roles of ARL6IP5 in cancers are controversial. In this mini-review, we summarized the current understanding on the role of ARL6IP5 in cancers, particularly in the progression of chronic hepatitis virus-related hepatocellular carcinoma, as well as the potential values of ARL6IP5 in cancer therapy.

Indexed as

ADP-Ribosylation FactorsNeoplasmsAnimalsHumansADP-Ribosylation Factors

Identifiers

PMID40253526
PMCPMC12277177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.